Compugen FY2026 Earnings Forecast Increased by HC Wainwright

Compugen Ltd. (NASDAQ:CGEN – Free Report) – Analysts at HC Wainwright lifted their FY2026 EPS estimates for Compugen in a research report issued on Thursday, November 12th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of ($0.31) per share for the year, up from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.39) EPS.

Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Compugen in a research report on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $5.00.

Get Our Latest Report on CGEN

Compugen Price Performance

Shares of CGEN stock opened at $2.10 on Monday. Compugen has a 12-month low of $1.43 and a 12-month high of $3.23. The firm has a fifty day moving average of $2.20 and a 200-day moving average of $2.29. The company has a market capitalization of $198.56 million, a price-to-earnings ratio of 5.38 and a beta of 2.85.

Compugen (NASDAQ:CGEN – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. Compugen had a net margin of 47.90% and a return on equity of 39.30%. The company had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same quarter in the prior year, the company earned ($0.07) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Calamos Advisors LLC acquired a new stake in Compugen in the 1st quarter valued at approximately $63,000. Hillsdale Investment Management Inc. bought a new stake in Compugen in the 1st quarter valued at approximately $68,000. Glenmede Trust Co. NA lifted its stake in Compugen by 187.5% in the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 22,500 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Compugen during the 2nd quarter worth approximately $110,000. Finally, Joel Isaacson & Co. LLC boosted its position in Compugen by 291.7% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 35,000 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors.

Compugen Company Profile

(Get Free Report)

Compugen Ltd. is an Israel-based clinical-stage biotechnology company focused on discovering and developing cancer immunotherapies. Founded in 1993, the company uses computational biology and related technologies to identify potential drug targets and develop antibody-based treatments. Its research centers on immune checkpoint pathways that can affect how the body’s immune system recognizes and attacks tumors. Compugen’s programs have included antibody candidates targeting PVRIG and TIGIT, among other potential therapies.

Read More

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.